SFJ XII (Nektar)

SFJ and Nektar agreed to co-developing Bempeg (IL-2) in a phase 3 clinical study in head and neck cancer in a clinical co-development deal. The investment entity for this is SFJ XII. Nektar subsequently discontinued all Bempeg studies due to failures in two other partnered indications. SFJ XII has ceased funding and will be wound down early.